People | September 20, 2024
Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
